Asthma in children treated with paracetamol versus ibuprofen: A systematic review and meta-analysis of randomised controlled trials

CURRENT STATUS: UNDER REVIEW

Mohamed Sherbash
Qatar University

Luis Furuya-Kanamori
Australian National University

Joanne Daghfal Nader
Qatar University

Lukman Thalib
Qatar University

Corresponding Author
Lthalib@qu.edu.qa
ORCID: https://orcid.org/0000-0002-1211-6495

DOI: 10.21203/rs.2.15808/v1

SUBJECT AREAS
Pulmonology

KEYWORDS
paracetamol, acetaminophen, ibuprofen, asthma, meta-analysis
Abstract
Background: Paracetamol and ibuprofen are the most commonly used medications for fever and pain management in children. While the efficacy appears similar with both drugs, there are contradictory findings related to adverse events. In particular, incidence of asthma among children taking paracetamol compared to ibuprofen, remain unsettled. Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) that compared asthma in children taking paracetamol versus ibuprofen. A comprehensive search was conducted in five databases. RCTs reporting on cases of asthma in infants or children after the administration of paracetamol or ibuprofen were included. The pooled effect size was estimated using the inverse variance heterogeneity model. Results: Five RCTs with 85095 children were included in the analysis. The pooled estimate (RR 1.04; 95%CI 0.84-1.29) revealed no difference in the risk of developing asthma or presenting an exacerbation of asthma in children who received paracetamol compared to ibuprofen. When the analysis was restricted to RCTs that examined the incidence of asthma, the pooled estimate remained similar (RR 1.03; 95%CI 0.64-1.67). Additional bias adjusted quality effect sensitivity model yielded similar results (RR 1.03; 95%CI 0.84-1.28). Conclusion: Ibuprofen and paracetamol have similar tolerance and safety profiles in terms of incidence of asthma in children.

Background
Paracetamol, also known as acetaminophen, is one of most commonly used over-the-counter medication to treat pain and fever. Paracetamol is perceived as a safe medication to control pain and fever in children, yet evidence from multiple epidemiological studies have shown a potential association between its use and asthma. An ecological study revealed that per-capita sale of paracetamol is associated with atopic diseases in children and adults. Analytical studies have found consistent results of an increased risk across difference populations as well as a dose-response relationship. A meta-analysis found the odds of wheezing doubles (OR 1.97; 95%CI 1.51-2.56) in children exposed to paracetamol.

The increasing evidence accumulated over the past 30 years about the risk of asthma associated with paracetamol has led clinicians to recommend a change in practice, particularly in children.
Among the alternatives to treat pain and fever in children, one that stands out is ibuprofen. A meta-analysis by Pierce and Voss found that ibuprofen is more effective in reducing pain and fever than paracetamol in paediatric population.\textsuperscript{14} They also reported that ibuprofen and paracetamol had similar rates of adverse events; however, they did not assess the risk of asthma.\textsuperscript{14} Ibuprofen as a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) and reduces prostaglandin synthesis. That in turn causes reduction in fever, inflammation, and pain. However, the inhibition of the COX pathway can also activate the lipoxygenase pathway, leading to an increase in leukotriene synthesis, and resulting in bronchospasms and asthma exacerbation.\textsuperscript{15}

The aim of this meta-analysis is to quantify the risk of asthma in paediatric population taking ibuprofen and paracetamol. Our findings are expected to help guide the paediatricians in management of fever and pain and drug choices.

**Methods**

Findings from this systematic review and meta-analysis are presented following the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The review was registered with the International Prospective Register of Systematic Reviews (CRD42017080165).

**Search strategy and study selection**

The search strategy was conducted in PubMed, Science Citation Index, Embase, Cochrane library, and ClinicalTrials.gov. The following search terms were included (paracetamol OR tylenol OR acetaminophen) AND ibuprofen AND (pediatrics OR children OR infants). All databases were searched from their inception until September 2017. The search was updated in July 2019 and was supplemented with a PubMed similarity search as well as a forwards and backwards citation search for the articles included in the meta-analysis. The references lists from relevant systematic reviews and meta-analyses were hand searched.

Eligible studies were RCTs conducted in humans that included paracetamol and ibuprofen within their study arms. To be considered for inclusion, the RCTs had to include children (£12 years) and reported the number of cases of asthma and/or asthma exacerbations. Studies were excluded if the study arms
included co-interventions (e.g. paracetamol plus codeine). No language restriction was applied. Two authors (MS and JN) independently screened the articles. Disagreement was resolved through consensus.

**Data extraction and quality assessment**

A spreadsheet was used for data extraction. The following items were extracted by one of the authors (MS) author, year of publication, study setting and characteristics of the study population, follow-up time, characteristics of the interventions (e.g. dose of medication), sample size, and number of cases of asthma. The extracted data was cross-checked by a second author (JD). The same two authors assessed the risk of bias of the RCTs using the Cochrane collaboration’s tool for assessing the bias in randomized trials.\(^{16}\)

**Statistical analysis**

The effect measure of interest was the relative risk (RR) of developing asthma after exposure to paracetamol compared to ibuprofen. Statistical heterogeneity among studies was assessed using the \(I^2\), an \(I^2 >50\%\) was considered substantial between-study heterogeneity. The pooled RR was estimated using the inverse variance heterogeneity (IVhet) model.\(^{17}\) Sensitivity analyses were conducted by excluding studies that measured exacerbation of asthma as their outcome as well as including the studies’ quality information (i.e. risk of bias) into the model through the quality effects (QE) model.\(^{18}\) Publication bias was investigated using the Doi plot and LFK index.\(^{19}\) The analysis was conducted in MetaXL version 5.3 (EpiGear Int Pty Ltd; Sunrise Beach; Australia; http://www.epigear.com).

**Results**

**Selection of studies**

The search identified 655 publications, 104 articles remained after title and abstract screening and the full text of the articles were examined to assess their eligibility. Eight publications met the
inclusion criteria. Four publications\textsuperscript{9,20-22} used subsets of the Boston University Fever Study data, only the publication with larger sample size\textsuperscript{20} was included in the meta-analysis. Therefore, five RCTs with 85095 children were included in the meta-analysis (Figure 1).

\textit{Characteristics of included studies}

Four RCTs were conducted in hosptails,\textsuperscript{23-26} while one was conducted in paediatric and family medicine practices.\textsuperscript{20} The age of the participants ranged from 2 months to 12 years with a mean age between 21 and 40 months. Four RCTs\textsuperscript{20,23,24,26} included only febrile children, their outcome of interest was episodes of asthma after the administration of paracetamol or ibuprofen, and had a relative short follow-up period ranging from 6 hours to 28 days. Sheehan et al.\textsuperscript{25} included afebrile children with asthma, thus the outcome of interest was exacerbation of asthma after receiving paracetamol or ibuprofen, and had a longer follow-up period of 48 weeks (Table 1). Overall, the risk of bias was low among the RCTs, the most common deficiency was blinding of outcome assessment, followed by allocation concealment and blinding of participants and personnel (Table 2).

\textit{Quantitative analysis}

The point estimates of two RCTs indicated lower risk of asthma with paracetamol,\textsuperscript{23,26} two RCTs point estimates indicated no difference,\textsuperscript{20,25} while the last RCT point estimate favoured the use of ibuprofen.\textsuperscript{24} No statistical heterogeneity among the five RCTs was observed. The pooled estimate (RR 1.04; 95%CI 0.84-1.29) revealed that there is no difference in the risk of developing asthma in children who received paracetamol compared to ibuprofen (Figure 2). When the analysis was restricted to RCTs that examined the episodes of asthma as their outcome of interest (i.e. excluding exacerbation of asthma), the pooled estimate did not change (RR 1.03; 95%CI 0.64-1.67). The QE model using the additional information from the quality assessment of each studies yielded similar results (RR 1.03; 95%CI 0.84-1.28). The Doi plot and the LFK index (-2.14) indicated major asymmetry
in favour of RCTs reporting less episodes of asthma with paracetamol compared to ibuprofen (Figure 3).

Discussion
Although efficacy, safety, and tolerability of ibuprofen and paracetamol in children have been investigated; only few studies have investigated the association between asthma and the use of these medications. After a comprehensive search, only five relevant RCTs were identified and included in this review, which points out to the paucity of data in this area of research. The pooled estimate indicates that there is no statistical nor clinically important differences between the use of ibuprofen or paracetamol in the paediatric population in relation to asthma morbidity. These null findings appear to be similar even among very young children. Lesko and Mitchell used a subset of their original data and compared the safety profile of these medications in children less than 2 years. They found that the risk of hospital admissions due to asthma/bronchiolitis was similar with ibuprofen and paracetamol. Such a negative findings support the theory that risk of asthma morbidity is similar with ibuprofen and paracetamol. Their study also showed that the effect is not modified by the age. This is particular pertinent as the sample size in their study (n=27065) was large with sufficient power to detect even a small differences, if existed between drugs.

Potential biological mechanisms that underpin the role of these drugs in asthma exacerbations have been postulated. Paracetamol is related to impaired lung function and asthma through a number of possible mechanisms; first being through oxidative stress. As paracetamol can lead to reduction of antioxidant glutathione concentration in the lungs, that can increase the oxidative stress in asthmatic patients. Bronchospasm through leukotriene release can be triggered by reactive oxygen species, which can greatly affect sensitive asthmatic patients. A second mechanism is related to the lack of COX-2 inhibition by paracetamol which can trigger immune mediated response through T helper cells which increase sensitivity to an allergic tendency to different stimuli. Another study suggested that the frequent use of paracetamol can result in consistent decrease in intracellular glutathione levels which can be linked to asthma morbidity. On the other hand, ibuprofen were thought to
induce asthma symptoms through COX-1 enzyme blockage which increases thromboxane production and decreases production of prostaglandins that have anti-inflammatory effect, leading to an increased release of pro-inflammatory leukotrienes which are chemical triggers for severe asthma exacerbations and allergy-like symptoms. Although, the plausible biological pathways for paracetamol and ibuprofen to produce bronchospasms are different, findings from our study revealed that the net effect in bronchospasms is similar between both medications.

Our findings should be understood in the light of a number of limitations. Although, there were no statistical heterogeneity encountered among the RCTs pooled in this study, potential clinical heterogeneities cannot be ruled out. It should also be noted that the severity of morbidity from asthma was not consistent across all studies as one RCT included “mild wheezing”, while another used asthma exacerbation that required systemic glucocorticoids as the outcome of interest. There were also variation in the dose of the interventions between RCTs as well as in the follow up time that ranged from 6 hours to 48 weeks.

Conclusions
We found no between asthma and exposure to paracetamol or ibuprofen in healthy or asthmatic children. Our finding is based on five RCTs as there were paucity of research in this area. As such, high quality trials with clear definition of asthma outcomes after receiving ibuprofen or paracetamol at varying doses with longer follow-up are warranted.

Abbreviations
CI - Confidence Interval
COX - Cyclooxygenase
IVhet - Inverse Variance Heterogeneity
LFK - Luis Furuya Kanamori
NSAID - Nonsteroidal Anti-Inflammatory Drug
OR - Odds Ratio
PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QE - Quality Effect
Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and material

Data sharing not applicable to this article as the data used in the current study was extracted from published studies.

Competing interests

The authors declare that they have no competing interests

Funding

LFK is funded by an Australian National Health and Medical Research Council Early Career Fellowship (APP1158469).

Authors' contributions

Conception and design of the study: MS and LT
Collection and assembly of the data: MS, LFK, JD
Analysis and interpretation: MS, LFK, JD, LT
Manuscript writing: MS, LFK, LT
Final approval of manuscript: All authors

References

1 Newson, R. B., Shaheen, S. O., Chinn, S. & Burney, P. G. J. Paracetamol sales and atopic disease in children adults: An ecological analysis. *Eur Respir J* **16**, 817-823 (2000).
2 Beasley, R. *et al.* Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme. *Lancet* **72**, 1039-1048 (2008).
3 Beasley, R. W. et al. Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International study of asthma and allergies in childhood phase three. *Am J Respir Crit Care Med* **183**, 171-178 (2011).

4 McKeever, T. M. et al. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. *Am J Respir Crit Care Med* **171**, 966-971 (2005).

5 Shaheen, S. et al. The relation between paracetamol use and asthma: A GA2LEN European case-control study. *Eur Respir J* **32**, 1231-1236 (2008).

6 Shaheen, S. O., Sterne, J. A. C., Songhurst, C. E. & Burney, P. G. J. Frequent paracetamol use and asthma in adults. *Thorax* **55**, 266-270 (2000).

7 Barr, R. G. et al. Prospective study of acetaminophen use and newly diagnosed asthma among women. *Am J Respir Crit Care Med* **169**, 836-841 (2004).

8 Amberbir, A. et al. The role of acetaminophen and geohelminth infection on the incidence of wheeze and eczema: A longitudinal birth-cohort study. *Am J Respir Crit Care Med* **183**, 165-170 (2011).

9 Lesko, S. M., Louik, C., Vezina, R. M. & Mitchell, A. A. Asthma morbidity after the short-term use of ibuprofen in children. *Pediatrics* **109**, E20 (2002).

10 Etminan, M. et al. Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis. *Chest* **136**, 1316-1323 (2009).

11 Allmers, H., Skudlik, C. & John, S. M. Acetaminophen use: A risk for asthma? *Curr Allergy Asthm R* **9**, 164-167 (2009).

12 Johnson, C. C. & Ownby, D. R. Have the efforts to prevent aspirin-related Reye's syndrome fuelled an increase in asthma? *Clin Exp Allergy* **41**, 296-298 (2011).

13 McBride, J. T. The association of acetaminophen and asthma prevalence and severity. *Pediatrics* **128**, 1181-1185, doi:10.1542/peds.2011-1106 (2011).

13 McBride, J. T. The association of acetaminophen and asthma prevalence and severity. *Pediatrics* **128**, 1181-1185 (2011).

14 Pierce, C. A. & Voss, B. Efficacy and safety of ibuprofen and acetaminophen in children and
adults: A meta-analysis and qualitative review. *Ann Pharmacother* **44**, 489-506 (2010).

15 Szczeklik, A. The cyclooxygenase theory of aspirin-induced asthma. *Eur Respir J* **3**, 588-593 (1990).

16 Higgins, J. P. *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, d5928 (2011).

17 Doi, S. A., Barendregt, J. J., Khan, S., Thalib, L. & Williams, G. M. Advances in the meta-analysis of heterogeneous clinical trials I: The inverse variance heterogeneity model. *Contemp Clin Trials* **45**, 130-138 (2015).

18 Doi, S. A. R., Barendregt, J. J., Khan, S., Thalib, L. & Williams, G. M. Advances in the meta-analysis of heterogeneous clinical trials II: The quality effects model. *Contemp Clin Trials* **45**, 123-129 (2015).

19 Furuya-Kanamori, L., Barendregt, J. J. & Doi, S. A. R. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthcare* **16**, 195-203 (2018).

20 Lesko, S. M. & Mitchell, A. A. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. *Jama* **273**, 929-933 (1995).

21 Lesko, S. M. & Mitchell, A. A. Renal function after short-term ibuprofen use in infants and children. *Pediatrics* **100**, 954-957 (1997).

22 Lesko, S. M. & Mitchell, A. A. The safety of acetaminophen and ibuprofen among children younger than two years old. *Pediatrics* **104**, e39 (1999).

23 Luo, S. *et al.* Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial. *Paediatric drugs* **19**, 479-486 (2017).

24 McIntyre, J. & Hull, D. Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. *Arch Dis Child* **74**, 164-167 (1996).

25 Sheehan, W. J. *et al.* Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. *N Engl J Med* **375**, 619-630 (2016).
26 Wong, A. et al. Antipyretic effects of dipyrrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. *Clin Pediatr* **40**, 313-324 (2001).

27 Southey, E. R., Soares-Weiser, K. & Kleijnen, J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. *Curr Med Res Opin* **25**, 2207-2222 (2009).

28 Nuttall, S., Khan, J., Thorpe, G., Langford, N. & Kendall, M. The impact of therapeutic doses of paracetamol on serum total antioxidant capacity. *J Clin Pharm Ther* **28**, 289-294 (2003).

29 Dworski, R. Oxidant stress in asthma. *Thorax* **55**, S51-S53 (2000).

30 Eneli, I., Sadri, K., Camargo, C., Jr. & Barr, R. G. Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic evidence. *Chest* **127**, 604-612 (2005).

31 Dimova, S., Hoet, P. H., Dinsdale, D. & Nemery, B. Acetaminophen decreases intracellular glutathione levels and modulates cytokine production in human alveolar macrophages and type II pneumocytes in vitro. *Int J Biochem Cell Biol* **37**, 1727-1737 (2005).

32 Levy, S. & Volans, G. The use of analgesics in patients with asthma. *Drug Saf* **24**, 829-841 (2001).

Tables

**Table 1.** Characteristics of the included randomised controlled trials
| Author, year   | Setting                                                                 | Study population                                                                 | Proportion of females (%) | Mean/median age (months) |
|---------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------|-------------------------|
| Lesko et al. 1995<sup>20</sup> | Outpatient paediatric and family medicine practice throughout the US (1991-1993) | Children aged 6 months to 12 years with acute febrile illness (Boston University Fever Study) | 48                        | 40                      |
| Luo et al. 2017<sup>23</sup> | Tertiary hospital in China (2013-2014)                                   | Febrile children aged 6 months to 5 years attending the emergency room           | 40                        | 30                      |
| McIntyre and Hull 1996<sup>24</sup> | Tertiary hospital in the UK                                               | Febrile children aged 2 months to 12 years                                       | 41                        | 21                      |
| Sheehan et al. 2016<sup>25</sup> | 18 hospitals in the US (2013-2015)                                       | Children aged 1 to 6 years receiving long-term step 2 asthma-controller therapy (The Acetaminophen versus Ibuprofen in Children with Asthma trial) | 40                        | 40                      |
| Wong et al. 2001<sup>26</sup>  | University hospitals in Argentina, Mexico, Chile, and Brazil (1998)       | Febrile children aged 6 months to 6 years                                         | 46                        | 30                      |

*Cases of asthma exacerbations

**Table 2. Assessment of risk of bias of the included randomised controlled trials**

| Author, year   | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete data |
|---------------|-----------------------------|------------------------|----------------------------------------|-------------------------------|-----------------|
| Lesko et al. 1995<sup>20</sup> | Low risk                   | Low risk               | Low risk                               | Low risk                      | Low             |
| Luo et al. 2017<sup>23</sup> | Low risk                   | Low risk               | High risk                              | High risk                     | Low             |
| McIntyre and Hull 1996<sup>24</sup> | Low risk                   | High risk              | High risk                              | High risk                     | Low             |
| Sheehan et al. 2016<sup>25</sup> | Low risk                   | Low risk               | Low risk                               | Low risk                      | High            |
| Wong et al. 2001<sup>26</sup>  | Low risk                   | High risk              | Low risk                               | High risk                     | Low             |

* Exposure and outcome assessment were considered low risk if the information was obtained from medical records or directly recorded by the investigators, and high risk if it was self-reported by the parents or guardians of the children.

The other items of the risk of bias were classified as low or high risk following the Cochrane collaboration’s tool for assessing risk of bias.

**Figures**
Figure 1

PRISMA flow diagram

Figure 2

Forest plot of the relative risk of asthma in children who received paracetamol compared to ibuprofen
Figure 3

Doi plot and LFK index for the detection of publication bias

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

PRISMA 2009 checklist.pdf